Patients with advanced prostate cancer are often treated with hormones, but when the tumours start growing again they have more and different blood vessels, reveals a thesis from the Sahlgrenska Academy, at the University of Gothenburg, Sweden. This discovery paves the way for new treatments for hormone-resistant prostate cancer. Late in the course of the disease, when the prostate cancer has spread, most patients are given hormone therapy. This reduces the production of the male sex hormone and the tumour shrinks. "The problem is that the effect is transient, " says molecular biologist HelĂ ne Gustavsson, who wrote the thesis. "Sooner or later the tumour will develop resistance to the hormone treatment and then the cancer will continue to grow, often as secondary tumours in the bones.
A recent study determined glucocorticoid-induced osteoporosis (OP) is now treatable with Teriparatide, a synthetic form of the human parathyroid hormone. Researchers found patients with glucocorticoid-induced OP who were treated with teriparatide for 36 months had a greater increase in bone mineral density (BMD) and fewer new vertebral fractures than those treated with alendronate. The findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR). Glucocorticoids are steroid hormones that are naturally produced in the body or synthetically created compounds (drugs) used to reduce inflammation.
Trophoblast stem cells (TSCs), cells found in the layer of peripheral embryonic stem cells from which the placenta is formed, are thought to exhibit "immune privilege" that aids cell survivability and is potentially beneficial for cell and gene therapies. Further, the survivability of TSCs has been thought to require the presence of ovarian hormones. However, none of these assumptions has ever been verified. This study, published in the current issue of the journal Cell Transplantation (18:7) - now freely available on-line here - has demonstrated that it is the absence of male hormones, rather than the presence of female hormones, that allows extended transplanted cell survivability.
UroToday.com - Management of patients with 46, XY cloacal exstrophy is becoming more controversial as long-term studies suggest that prenatal testosterone exposure may imprint the brains of these children prior to puberty, and contributes to male sexual identity. While identifying the cryptorchid testis with the latest imaging preoperatively would be ideal, the current imaging modalities including US and MRI are not very sensitive to detect cryptorchid testis in both the isolated cryptorchidism and cloacal extrophy patient populations. This case report demonstrates the challenges associated with identifying a cryptorchid testis in a 17 year old 46, XY patient with cloacal exstrophy, and provides one example where prenatal and postnatal testosterone exposure did not correlate with male sexual identity, further contributing to the ongoing controversy surrounding gender assignment in this patient population.
A common type of chronic diarrhoea may be caused by a hormone deficiency, according to new research published in the November issue of Clinical Gastroenterology and Hepatology. The authors of the paper, from Imperial College London, with collaborators from King's College London and the University of Edinburgh, say their results could help more doctors recognise this type of diarrhoeal illness, and may lead to the development of more effective tests and treatments to help improve the lives of many people suffering with chronic diarrhoea. Chronic idiopathic bile acid diarrhoea affects an estimated one in 100 people in the UK and it can cause people to have up to ten watery bowel movements a day, often for months at a time.
Penn Medicine will lead a new national $45 million clinical trial to test whether testosterone therapy can favorably affect certain conditions affecting older men. Low serum testosterone may contribute to a number of problems affecting older men, including decreased ability to walk, loss of muscle mass and strength, decreased vitality, decreased sexual function, impaired cognition, cardiovascular disease and anemia. While testosterone normally decreases with age, in some men, low levels of testosterone may contribute to these debilitating conditions. Led by the University of Pennsylvania School of Medicine and conducted at 12 sites across the nation, the Testosterone Trial will involve 800 men age 65 and older with low testosterone levels.